Specifically, a meta-analysis of the ELIXA, LEADER, SUSTAIN-6, EXSCEL, REWIND and AMPLITUDE-O trials in type 2 diabetes estimated a 21% reduction in the risk of new-onset macroalbuminuria, eGFR decline, progression to ESKD or death attributable to kidney causes with GLP1-RAs compared with placebo [48]
When pharmaceutical companies put profits before people's health, victims deserve attorneys who will fight without backing down
No one wants to ask the hardest question: What if the real upside here has nothing to do with how you look in 90 days, and everything to do with how your vasculature, kidneys, liver, and brain behave over decades? If GLP-1s end up adding meaningful healthy years, history will show that the current Ozempic discourse completely missed the point
So steer clear of products with high alcohol content or products that make skin become dryer as they will trigger the oil glands to then produce more oil
This flexibility helps healthcare providers find the best medication and dose for your individual needs and goals
Clinical data shows a clear dose-dependent pattern
